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Upregulation of arylsulfatase B in 
carotid atherosclerosis is associated 
with symptoms of cerebral 
embolization
Erik Biros1, Corey S. Moran1, Jane Maguire2, Elizabeth Holliday3, Christopher Levi4 &  
Jonathan Golledge1,5
The aim of this study was to identify genes for which the expression within carotid atherosclerosis 
was reproducibly associated with the symptoms of cerebral embolization. Two publically available 
microarray datasets E-MEXP-2257 and GSE21545 were analysed using GeneSpring 11.5. The two 
datasets utilized a total of 22 and 126 carotid atherosclerosis samples, obtained from patients with 
and without symptoms of cerebral embolization, respectively. To assess whether the findings were 
reproducible we analysed carotid atherosclerosis samples from another 8 patients with and 7 patients 
without symptoms of cerebral embolization using real-time PCR. In vitro studies using VSMC were 
performed to assess the functional relevance of one of the validated genes. We identified 1624 and 135 
differentially expressed genes within carotid atherosclerosis samples of symptomatic compared to 
asymptomatic patients using the E-MEXP-2257 and GSE21545 datasets, respectively (≥1.15-absolute 
fold-change, P < 0.05). Only 7 differentially expressed genes or 0.4% (7/1,752) were consistent between 
the datasets. We validated the differential expression of ARSB which was upregulated 1.15-fold 
(P = 0.029) in atherosclerosis from symptomatic patients. In vitro incubation of VSMCs with the ARSB 
inhibitor L-ascorbic acid resulted in marked upregulation of SIRT1 and AMPK. This study suggests that 
ARSB may represent a novel target to limit carotid embolization.
The prevalence of carotid artery stenosis is approximately 4% to 8% in adults aged 50 to 79 years1–3. Carotid 
atherosclerosis is estimated to be responsible for ~20% of all ischemic strokes4, 5. Atherosclerotic plaque rupture 
and cerebral embolization is believed to be the mechanism by which carotid atherosclerosis leads to cerebral 
symptoms, such as transient ischemic attack and stroke1. However, the identification of the so-called “vulnerable 
plaque” has been elusive. The first whole-genome gene expression study of stroke was published a decade ago6. 
The authors at that time profiled peripheral blood mononuclear cells of stroke patients and compared them with 
those of healthy donors6. Almost 200 differentially expressed genes were identified; however, those assessed had 
limited diagnostic value with estimated specificity and sensitivity less than 80%6. A number of previous studies 
have examined differential gene expression in symptomatic carotid atherosclerosis; however, findings have not 
been consistent across the studies7–15. All these results question the value of differential gene expression in repre-
senting true molecular determinants of stroke. The current study re-examined previously published microarray 
datasets of carotid artery atherosclerosis to gain further insight. An attempt has been made to identify consistent 
and reproducible differentially expressed genes using publically available microarray datasets that utilized carotid 
endarterectomy samples from symptomatic and asymptomatic patients.
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Methods
Data preparation. Two human microarray datasets were included in this study to establish a consensus 
set of differentially expressed genes in carotid atherosclerosis associated with the recent symptoms of cerebral 
embolization12, 13. Suitable datasets were required to be publically available, to assess whole-genome gene expres-
sion within carotid plaque biopsies from patients both with and without symptoms of cerebral embolization, 
and to use commercially available microarrays of the same chip platform. The publically available raw array data 
were downloaded from Gene Expression Omnibus (GEO) provided by the National Center for Biotechnology 
Information (NCBI) or ArrayExpress provided by the European Molecular Biology Laboratory-European 
Bioinformatics Institute (EMBL-EBI) public repositories.
Re-analysis of the original array data. In order to identify differentially expressed genes in carotid ather-
osclerotic tissue between symptomatic and asymptomatic patients, we analysed each original microarray dataset 
as described previously16. Briefly, the raw data matrix downloaded from GEO or ArrayExpress public reposi-
tories was uploaded into GeneSpring GX 11.5 (Agilent Technologies Pty Ltd) and the standard normalization 
procedures recommended for the Affymetrix GeneChip arrays was followed. Expression values were normalized 
using percentile shift normalization with default settings. These included normalization to 75th percentile. The 
expression profile of carotid atherosclerosis samples obtained from participants with symptoms of cerebral embo-
lization was compared to those without symptoms. Since all samples represented advanced atherosclerotic tissue, 
only small differences in gene expression were expected between patients with and without symptoms of cerebral 
embolization. Previous evidence suggested that small changes in gene expression are able to induce significant 
phenotypic differences17. In line with this, genes with ≥1.15-absolute fold differential expression between groups 
based on P-value < 0.05 by non-parametric Mann–Whitney U-test with no mathematical correction for multiple 
testing were considered to be differentially expressed.
Validation of microarrays findings. Using total RNA obtained from atherosclerosis removed from 
the proximal internal carotid (PIC) arteries of 8 patients with and 7 patients without symptoms of cerebral 
embolization, we assessed the validity of microarray findings (validation group). Total RNA was extracted 
from PIC biopsies stored in RNAlater (Sigma-Aldrich) at −80 °C using RNeasy Mini Kit (Qiagen) according 
to manufacturer’s instructions. Symptomatic patients presented with focal neurological symptoms related to 
their anterior cerebral circulation such as transient ischemic attack (TIA) or stroke within 6 weeks of surgery; 
asymptomatic patients presented with no history of neurological symptoms1. Quantitative real-time reverse 
transcription PCR (qRT-PCR) assay was performed to assess the relative expression of arylsulphatase B (ARSB) 
as this was consistently differential expressed in the array analyses. The relative expression of ARSB in each 
sample was calculated by using the Concentration-Ct-standard curve method and normalized using the aver-
age expression of the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene for each sample using the 
Rotor-Gene Q operating software version 2.0.24 (Qiagen). GAPDH was chosen as the “housekeeping” gene 
since analyses showed its expression to be similar in carotid biopsies from symptomatic and asymptomatic 
patients. The QuantiTect SYBR Green one-step RT-PCR Kit (Qiagen) was used according to the manufactur-
er’s instructions with 20 ng of total RNA as template. All reactions were independently repeated in duplicate 
to assess the repeatability of the results and the mean of the two values for each sample was used for analyses. 
The QuantiTect Primer Assays QT00026684 and QT00079247 (Qiagen) were used for the ARSB and GAPDH 
assessments, respectively. Mann–Whitney U test was performed to identify differences in expression levels of 
ARSB between carotid atherosclerosis biopsies of patients with and without symptoms of cerebral emboliza-
tion. Data were presented as box-and-whisker plots with median and interquartile range with maximum and 
minimum data points (whiskers) for relative expression. Statistical significance was defined at the conventional 
5% level. All computations were performed using the Stata/MP 13.1 statistical software (StataCorp LP, USA). 
Ethical approval was granted from The Townsville Hospital (TTH) and Health Services Committees, written 
informed consent was obtained from each participant, and the protocols conformed to the ethical guidelines 
of the Declaration of Helsinki.
Cell culture. We investigated the effects of chondroitin sulphate, a natural substrate for ARSB, and L-ascorbic 
acid, an ARSB inhibitor, on the expression of sirtuin 1 (SIRT1) and protein kinase AMP-activated catalytic subu-
nit alpha 1 (PRKAA1 or AMPK, 5′-prime-AMP-activated protein kinase) under inflammatory conditions in vitro. 
These two ARSB-associated bioactive molecules were specifically selected to test their individual and combined 
ability to upregulate the SIRT1/AMPK metabolic pathway that exerts strong anti-inflammatory, anti-atherogenic, 
and plaque-stabilizing effects18, 19. We used human vascular smooth muscle cells (VSMC; Clonetics) that were 
plated at a seeding density of 1 × 105 cells/well and maintained at 37 °C, 5% CO2, in Dulbecco’s Modified Eagle 
Medium (DMEM; Sigma-Aldrich) containing 10% fetal bovine serum (FBS; Gibco). Cells were growth arrested at 
90% confluency by incubation in DMEM + 0.1% FBS overnight (18 hours). Control cultures (n = 6) were exposed 
to DMEM + 10% FBS comprising 10% v/v conditioned media generated from human monocytic THP-1 cells 
exposed to 10 µg/ml endotoxin (Lipopolysaccharide; Sigma-Aldrich) over a period of 24 hours. Experimental 
cultures were exposed to the same pro-inflammatory media but supplemented with either L-ascorbic acid 
(Sigma-Aldrich; 400 μM; n = 6 cultures) or chondroitin sulphate sodium salt (Sigma-Aldrich; 300 μM; n = 6 
cultures), or a combination of both (n = 6 cultures). All cells were harvested after a 24-hour experimental period 
and subjected to RNA extraction followed by qRT-PCR using the Qiagen’s QuantiTect Primer Assay QT00009436 
(AMPK) and QT00051261 (SIRT1) as outlined above.
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Results
Datasets characteristics. Two whole-genome gene expression datasets were included in this study to 
determine the consensus set of differentially expressed genes in carotid atherosclerosis associated with the symp-
toms of cerebral embolization (Table 1). The E-MEXP-2257 dataset utilized 22 carotid plaque biopsies obtained 
from 13 and 9 patients with and without symptoms of cerebral embolization, respectively. The summary charac-
teristics of participants included in the E-MEXP-2257 dataset are presented elsewhere12. In brief, the mean age of 
patients was 64 ± 8 years, ~27% of participants were females (6/22), and ~27% of participants (6/22) had a posi-
tive history of smoking (Table 1). The second dataset included in this study, GSE21545, utilized 126 carotid plaque 
biopsies obtained from 25 and 101 symptomatic and asymptomatic patients, respectively (Table 1). The summary 
characteristics of participants included in the GSE21545 dataset are presented elsewhere13. Briefly, the mean age 
of patients was 71 ± 9 years, ~22% of participants were females (28/126), and ~49% of participants (62/126) had 
a positive history of smoking (Table 1). No individual patient’s clinical characteristics, including medication and 
severity of carotid atherosclerosis, were publically available for both datasets.
Numerical assessment of differentially expressed genes. The E-MEXP-2257 and GSE21545 
microarray datasets were individually re-analysed to identify differentially expressed genes and the overlap 
between the findings. A total of 1,624 and 135 genes were found to be differentially expressed (≥1.15-absolute 
fold change, uncorrected P < 0.05) within carotid plaques of symptomatic compared to asymptomatic patients 
in E-MEXP-2257 and GSE21545, respectively (Fig. 1). Full lists of differentially expressed genes are given in 
Supplemental Table I and Supplemental Table II for E-MEXP-2257 and GSE21545, respectively. Although 
E-MEXP-2257 and GSE21545 collectively identified 1,752 differentially expressed individual genes, only 7 genes 
or 0.4% were consistently differentially expressed in the two datasets (7/1,752; Fig. 1).
Data set E-MEXP-2257 GSE21545
Reference 12 13
Technology used Affymetrix GeneChip HG-U133A Affymetrix GeneChip HG-U133 Plus 2
Number of transcripts analysed 18,400 47,000
Sample analysed Carotid plaque biopsies Carotid plaque biopsies
Number of patients 22 126
Number of symptomatic patients 13 (59%) 25 (20%)
Age (years) 64 ± 8 71 ± 9
Number of females 6 (27%) 28 (22%)
Number of current or previous smokers 6 (27%) 62 (49%)
Table 1. Characteristics of two microarray datasets included in this study. Age, calendar age at entry-to-study 
presented as mean ± standard deviation (SD).
Figure 1. Numerical assessment of genes for which the expression in carotid atherosclerosis was associated 
with the symptoms of cerebral embolization. Venn diagram illustrating the overlap between the E-MEXP-2257 
and GSE21545 microarray datasets profiling differentially expressed genes within carotid plaque biopsies. 
Samples obtained from patients with symptoms of cerebral embolization were compared with those of patients 
without the symptoms (≥1.15-absolute fold difference, P < 0.05 without mathematical correction for multiple 
comparisons calculated with non-parametric Mann-Whitney test).
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Assessment of consistently differentially expressed genes. Inspection of the differentially expressed 
genes revealed that the arylsulfatase B (ARSB) gene was the only gene consistently upregulated in sympto-
matic compared to asymptomatic patients identified in both E-MEXP-2257 (1.15-fold change, P = 0.039) and 
GSE21545 (1.15-fold change, P = 0.030) datasets (Table 2). The coagulation factor III, tissue factor (F3) gene and 
the ubiquitin like modifier activating enzyme 6 (UBA6) gene were found to be upregulated in symptomatic com-
pared to asymptomatic patients in the E-MEXP-2257 dataset but downregulated in symptomatic compared to 
asymptomatic patients in the GSE21545 dataset (Table 2). The growth arrest specific 6 (GAS6) gene, the unchar-
acterized LOC730101 (LOC730101), and the secretory leukocyte peptidase inhibitor (SLPI) gene were identified 
to be downregulated in symptomatic compared to asymptomatic patients in both datasets (Table 2). Finally, the 
G protein-coupled receptor 135 (GPR135) gene was found to be downregulated in symptomatic compared to 
asymptomatic patients in the E-MEXP-2257 dataset but upregulated in symptomatic compared to asymptomatic 
patients in the GSE21545 dataset (Table 2).
Validation of microarray findings. The validity of microarray findings was further assessed using carotid 
atherosclerosis biopsies obtained from 8 symptomatic and 7 asymptomatic patients undergoing carotid endarter-
ectomy (validation group; Table 3). The risk factors and medications of symptomatic and asymptomatic patients 
were similar (Table 3). The relative expression of ARSB, the only gene consistently upregulated in symptomatic 
compared to asymptomatic patients in both microarray datasets, was also found to be significantly increased 
within the carotid atherosclerotic tissue of symptomatic compared to asymptomatic patients of the validation 
group using qRT-PCR (*P = 0.029; Fig. 2).
Cell culture. Finally, we investigated the effect of chondroitin sulphate (ARSB substrate) and L-ascorbic acid 
(ARSB inhibitor) on important anti-atherogenic pathways represented by the AMPK and SIRT1 genes using 
human VSMC in vitro under inflammatory conditions. We found that incubation of VSMC with L-ascorbic acid 
was associated with upregulation of both AMPK (Fig. 3A) and SIRT1 (Fig. 3B). The incubation of VSMC with 
chondroitin sulphate was associated with upregulation of SIRT1 (Fig. 3B) but not AMPK (Fig. 3A). Importantly, 
the simultaneous incubation of VSMC with chondroitin sulphate and L-ascorbic acid resulted in synergistic 
upregulation of AMPK (Fig. 3A) and additive upregulation of SIRT1 (Fig. 3B). These findings suggest that the 
combination of chondroitin sulphate and L-ascorbic acid may represent a potent activator of the AMPK/SIRT1 
pathways.
Gene symbol Gene name
E-MEXP-2257 dataset GSE21545 dataset
Fold change Regulation P-value Fold change Regulation P-value
ARSB arylsulfatase B 1.15 Up 0.039 1.15 Up 0.030
F3 coagulation factor III, tissue factor 1.26 Up 0.019 −1.20 Down 0.035
GAS6 growth arrest specific 6 −1.42 Down 0.011 −1.18 Down 0.032
GPR135 G protein-coupled receptor 135 −1.21 Down 0.004 1.17 Up 0.012
LOC730101 uncharacterized LOC730101 −1.16 Down 0.006 −1.20 Down 0.025
SLPI secretory leukocyte peptidase inhibitor −1.27 Down 0.013 −1.35 Down 0.018
UBA6 ubiquitin like modifier activating enzyme 6 1.20 Up 0.039 −1.39 Down 0.032
Table 2. Genes for which the expression in carotid atherosclerosis was consistently associated with the 
symptoms of cerebral embolization in the two microarray datasets included in this study. P-value, calculated 
with non-parametric Mann-Whitney test without mathematical correction for multiple comparisons.
Characteristic Symptomatic patients Asymptomatic patients P-value
Number of patients 8 7 —
Age (years) 72 ± 11 72 ± 5 0.779
Number of females 2 (25%) 1 (14%) 0.677
Number of current or previous smokers 7 (88%) 6 (86%) 0.933
Type 2 diabetes 3 (38%) 1 (14%) 0.390
Hypertension 6 (75%) 5 (71%) 0.962
Ischemic heart disease 3 (38%) 3 (43%) 0.853
Dyslipidaemia 5 (63%) 4 (57%) 0.853
Statins 5 (63%) 3 (43%) 0.505
Fibrates 0 (0%) 2 (29%) 0.200
Angiotensin converting enzyme inhibitors 2 (25%) 5 (71%) 0.109
Angiotensin receptor blockers 2 (25%) 1 (14%) 0.462
Table 3. Risk factors and medication of patients with and without symptoms of cerebral embolization included 
in the validation group. Nominal variables are presented as numbers; continuous variables are presented as 
mean ± standard deviation. Two-sided P value calculated by Mann Whitney U test (continuous variables) or 
Fisher’s exact test (nominal variables).
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Discussion
We analysed publically available microarray datasets from previous gene expression studies that utilised carotid 
plaque biopsies from patients with and without symptoms of cerebral embolization12, 13. By focusing on genes 
that were simultaneously differentially expressed in the datasets analysed, we were able to discover and validate 
the upregulation of ARSB in carotid plaques of symptomatic compared to asymptomatic patients, not acknowl-
edged in the original microarray studies. It is important to note that the protein product of this gene is involved 
in degradative processes of sulphated proteoglycans, the major component of virtually all extracellular matrices 
(ECMs)20. Furthermore, previous data suggest an inverse association between enzymatic activity of ARSB and 
the stability of sulphated proteoglycans within the ECM21. In line with this, Koledgie et al. found that plaque 
rupture sites contain very little proteoglycan content relative to stable lesions22, consistent with a degradative 
process.
Although the upregulation of ARSB within the carotid plaque biopsies of symptomatic patients identified in 
both microarray datasets was relatively small, we were able to confirm these findings by qRT-PCR using carotid 
plaque biopsies obtained from another group of symptomatic and asymptomatic patients. This led us to hypoth-
esize that upregulation of ARSB may represent an important pathological mechanism associated with symptoms 
of cerebral embolization, consistent with previous findings that even small changes in gene expression can induce 
major phenotypic differences17. The ARSB enzyme catalyses de-sulphation of ubiquitous glycosaminoglycans 
such as chondroitin sulphate23. Published evidence suggests that plasma concentration of under-sulphated chon-
droitin is elevated in patients with carotid artery disease24, while sulphated chondroitin has been long known 
to exhibit anti-atherogenic properties in rodents, primates, and humans25–28. Several historical studies from the 
1960s and 1970s report reduced incidence of coronary events and cardiovascular mortality in atherosclerotic sub-
jects treated with chondroitin sulphate28–30. Recent data suggests that anti-atherogenic actions of chondroitin sul-
phate may occur through interfering with the pro-inflammatory activation of monocytes and endothelial cells by 
tumor necrosis factor (TNF) alpha31, a cytokine thought to be crucially involved in the pathogenesis of atheroscle-
rotic plaque32. Although the authors did not elucidate the exact mechanism of action of chondroitin sulphate31, it 
is possible that upregulation of anti-inflammatory microRNAs, the negative regulators of gene expression, could 
play a role33–35. Previous studies suggest an inhibitory effect of chondroitin sulphates on gene expression through 
modification of microRNAs36. Importantly, the ARSB enzyme is inhibited by L-ascorbic acid21, 37. Due to the 
lack of a well-developed animal model of carotid atherosclerosis associated with cerebral embolization, we fur-
ther investigated the effect of L-ascorbic acid and chondroitin sulphate on important anti-atherogenic pathways 
in vitro. We found that chondroitin sulphate and L-ascorbic acid administered together induced a remarkable 
upregulation in the expression of SIRT1 and AMPK genes in VSMCs exposed to inflammatory conditions in vitro. 
These findings suggest that chondroitin sulphate formulated with L-ascorbic acid may serve as a potent activator 
of the SIRT1/AMPK pathway. This may hold promise as a novel therapeutic approach for carotid atherosclerosis 
since the SIRT1/AMPK pathway is key to a number of vasculoprotective processes. In particular, SIRT1 is the 
nicotinamide adenosine dinucleotide (NAD)-dependent deacetylase that has been associated with inhibition 
of the proatherogenic VSMC foam cell formation possibly through the suppressing of the nuclear factor kappa 
B (NF-κB) signalling pathway38. AMPK is the main energy-sensing kinase in all eukaryotic cells and has been 
implicated in stabilizing atherosclerotic plaques through the inhibition of the mammalian target of rapamycin 
(mTOR) signalling pathway39. The downregulation of genes for secretory leukocyte peptidase inhibitor (SLPI), 
uncharacterized LOC730101, and growth arrest specific 6 (GAS6) in carotid atherosclerosis associated with the 
symptoms of cerebral embolization in both datasets included in this study was also demonstrated. The role of 
SLPI and LOC730101 in human carotid atherosclerosis is largely unknown. Some evidence suggests that more 
Figure 2. Expression of the ARSB gene within carotid atherosclerosis of patients with and without symptoms of 
cerebral embolization. Increased expression of ARSB within carotid atheroma biopsies of symptomatic (N = 8) 
compared to asymptomatic (N = 7) patients (*P = 0.029). Data expressed as median and interquartile range 
with maximum and minimum data points (whiskers) for relative expression and compared by Mann-Whitney 
U test.
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severe atherosclerosis in humans is associated with an increase in GAS6 expression40, while similar expression of 
GAS6 in human carotid arteries with and without atherosclerosis has been reported41. Further investigation of the 
role of these three genes in carotid atherosclerosis is needed.
The limitations of this study include the relatively small number of patients included in the original microar-
ray datasets. In particular, although both datasets collectively included 148 carotid atherosclerosis tissue samples, 
the total number of 38 ischemic events was relatively small and findings need to be substantiated by larger studies. 
We also observed very limited overlap and consistency between the genes differentially expressed in the two 
datasets suggesting the heterogeneous nature of the patients investigated. Further genome-wide gene expression 
studies involving histologically standardized sets of patients are needed. In view of these limitations we sought to 
validate important microarrays finding using another set of carotid artery biopsies obtained from patients with 
and without symptoms of cerebral embolization. The assessment of independent samples helps to minimize the 
possibility that selection biases adversely affected the generalizability of the findings. We did, however, only assess 
mRNA not protein levels due to limited availability of carotid artery biopsies. Finally, the exact mechanism by 
which chondroitin sulphate combined with L-ascorbic acid upregulated the SIRT1/AMPK pathway as well as the 
therapeutic doses of these two bioactive molecules remains to be elucidated.
In conclusion, a decade after the first microarrays for stroke, its molecular determinants are still poorly under-
stood. The outcome of this study highlight a potential role for arylsulfatase B in promoting atherosclerosis-related 
stroke and warrants its further investigation as a therapeutic target that could be of potential clinical benefit.
Figure 3. Effect of L-ascorbic acid and chondroitin sulphate on AMPK and SIRT1 expression in inflammation-
activated VSMC in vitro. Upregulation of AMPK (A) (*P = 0.041, **P = 0.002) and SIRT1 (B) (*P = 0.015, 
**P = 0.002) in VSMCs incubated with L-ascorbic acid (L-AA) and chondroitin sulphate (CS) compared to 
control. Data expressed as median and interquartile range with maximum and minimum data points (whiskers) 
for relative expression and compared by Mann-Whitney U test.
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